Možnosti ovlivnění inzulinové rezistence u jedinců s diabetem 1. typu
Authors:
D. Karásek
Authors‘ workplace:
III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in:
Kardiol Rev Int Med 2018, 20(2): 126-130
Overview
Some data show that the prevalence of obesity in patients with type 1 diabetes increases faster than in the general population. There is an increasing number of patients with insulin resistance playing an important role in the pathogenesis of adverse metabolic changes that contribute to the acceleration of cardiovascular complications. Non-pharmacological interventions leading to positive changes in lifestyle represent an integral part of diabetes treatment. The paper is focused on the current possibilities of insulin resistance improvement in type 1 diabetics, especially on pharmacological agents including antidiabetics that are primarily intended for type 2 diabetes.
Key words:
type 1 diabetes – insulin resistance – metabolic syndrome – insulin – metformin – thiazolidinediones – incretins – gliflozins
Sources
1. Národní zdravotnický informační systém – ambulantní péče. Stručný přehled činností oboru diabetologie a endokrinologie za období 2007– 2015. NZIS REPORT č. K/ 1 (09/ 2016). https:/ / www.uzis.cz/ system/ files/ NZIS_REPORT_c_K1_09_16_A004 diabet_endokrin.pdf
2. Australia’s health 2016. AIHW National (insulin-treat-ed) Diabetes Register. https:/ / www.aihw.gov.au/ reports/ australias-health/ australias-health-2016/ contents/ chapter-3-leading-causes-of-ill-health.
3. Karásek D. Inzulínová rezistence u pacientů s diabetem 1. typu. In: Kvapil M (ed). Diabetologie 2018. Praha: Triton 2018: 89– 105.
4. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism 2015; 64(12): 1629– 1639. doi: 10.1016/ j.metabol.2015.09.002.
5. Chillarón JJ, Flores Le-Roux JA, Benaiges D et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014; 63(2): 181– 187. doi: 10.1016/ j.metabol.2013.10.002.
6. Cleland SJ, Fisher BM, Colhoun HM et al. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia 2013; 56(7): 1462– 1470. doi: 10.1007/ s00125-013-2904-2.
7. Gingras V, Leroux C, Fortin A et al. Predictors of cardiovascular risk among patients with type 1 diabetes: A critical analysis of the metabolic syndrome and its components. Diabetes Metab 2017; 43(3): 217– 222. doi: 10.1016/ j.diabet.2016.10.007.
8. Alberti KG, Eckel RH, Grundy SM et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640– 1645. doi: 10.1161/ CIRCULATIONAHA.109.192644.
9. Fernández-Miró M, Chillarón JJ, Albareda M et al. TEST-T1D study group. Hypertriglyceridemic waist in type 1 diabetes patients: prevalence and related factors. Minerva Endocrinol 2017; 42(1): 1– 7. doi: 10.23736/ S0391-1977.16.02561-X.
10. Schechter R, Reutrakul S. Management of severe insulin resistance in patients with type 1 diabetes. Curr Diab Rep 2015; 15(10): 77. doi: 10.1007/ s11892-015-0641-2.
11. Lyons SK, Hermann JM, Miller KM et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and t1d exchange registries. Diabetes Care 2017; 40(10): e139– e140. doi: 10.2337/ dc17-0403.
12. Nathan DM, Genuth S, Lachin J et al. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977– 986. doi: 10.1056/ NEJM199309303291401.
13. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643– 2653. doi: 10.1056/ NEJMoa052187.
14. Mottalib A, Kasetty M, Mar JY et al. Weight management in patients with type 1 diabetes and obesity. Curr Diab Rep 2017; 17(10): 92. doi: 10.1007/ s11892-017-0918-8.
15. Liu HY, Cao SY, Hong T et al. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem 2009; 284(40): 27090– 27100. doi: 10.1074/ jbc.M109.016675.
16. Dornhorst A, Luddeke HJ, Sreenan S et al. Insulin detemir improves glycaemic kontrol without weight gain in insulin-naive patientswith type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62(4): 659– 665. doi: 10.1111/ j.1742-1241.2008.01715.x.
17. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98(3): 1154– 1162. doi: 10.1210/ jc.2012-3249.
18. Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/ mL versus glargine 100 units/ mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015; 38(12): 2217– 2225. doi: 10.2337/ dc15-0249.
19. Liu C, Wu D, Zheng X et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(2): 142– 148. doi: 10.1089/ dia.2014.0190.
20. Petrie JR, Chaturvedi N, Ford I et al. REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5(8): 597– 609. doi: 10.1016/ S2213-8587(17)30194-8.
21. Tafuri KS, Godil MA, Lane AH et al. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013; 5(4): 236– 239. doi: 10.4274/ Jcrpe.981.
22. Zdravkovic V, Hamilton JK, Daneman D et al. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr 2006; 149(6): 845– 849. doi: 10.1016/ j.jpeds.2006.08.049.
23. Bhat R, Bhansali A, Bhadada S et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007; 78(3): 349– 354. doi: 10.1016/ j.diabres.2007.04.012.
24. Stone ML, Walker JL, Chisholm D et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatr Diabetes 2008; 9 (4 Pt 1): 326– 334. doi: 10.1111/ j.1399-5448.2008.00383.x.
25. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005; 28(7): 1562– 1567.
26. Guclu M, Oz Gul O, Cander S et al. Effect of rosiglitazone and insulin combination therapy on inflammation parameters and adipocytokine levels in patients with type 1 DM. J Diabetes Res 2015; 2015: 807891. doi: 10.1155/ 2015/ 807891.
27. Guo H, Fang C, Huang Y et al. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016; 121: 184– 191. doi: 10.1016/ j.diabres.2016.08.022.
28. Wang W, Gao Y, Chen D et al. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2017; 129: 213– 223. doi: 10.1016/ j.diabres.2017.05.007.
29. Chen J, Fan F, Wang JY et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017; 7: 44128. doi: 10.1038/ srep44128.
30. Garg SK, Henry RR, Banks P et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377(24): 2337– 2348. doi: 10.1056/ NEJMoa1708337
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2018 Issue 2
Most read in this issue
- Arrhythmias in young adults
- Juvenile hypertension
- Fixed dose combination of rosuvastatin and ezetimibe – drug profile
- Chronic venous insufficiency and varicose veins in young people